Print Friendly, PDF & Email

NCT/Study#

NA /

GDC-0084

A Phase 2 Study Of Paxalisib (GDC-0084) In Recurrent Or Refractory Primary Central Nervous System Lymphoma (PCNSL)

DISEASE GROUP:
Neuro-Oncology
current phase:
Phase II
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: